Evident Vascular, a San Jose, CA-based medtech company developing an AI-powered intravascular ultrasound (IVUS) platform, has secured Series B funding.
Investors
The round includes new investors, Shangbay Capital, and two undisclosed multinational strategics, joining founding investor Vensana Capital.
ShangBay Capital is a venture capital firm founded in 2015 and based in Palo Alto, California. The firm specializes in early-stage investments within the life sciences sector, focusing on medical devices, biotechnology, and digital health companies across the United States.
Vensana Capital is a venture capital and growth equity investment firm dedicated to partnering with entrepreneurs who seek to transform healthcare with breakthrough innovations in medical technology. Founded in 2019, Vensana has approximately $1 billion in capital under management.
Evident Vascular Use of Funds
The investment will accelerate the development of Evident Vascular’s advanced IVUS technology, support regulatory clearance, and prepare for commercialization in the U.S. market.
About Evident Vascular
Evident Vascular is a medical technology company focused on developing an AI-powered intravascular ultrasound (IVUS) platform to enhance vascular imaging and patient outcomes. The company leverages artificial intelligence (AI) to enhance image interpretation and streamline workflows, aiming to improve clinical outcomes in peripheral and coronary vascular interventions. Headquartered in San Jose, California, Evident Vascular’s mission is to empower clinicians with cutting-edge tools that enable precision, efficiency, and superior patient care.
Funding Details
Company: Evident Vascular, Inc.
Raised: Undisclosed
Round: Series B
Funding Date: March 2025
Investors: Shangbay Capital, Vensana Capital
Company Website: https://evidentvascular.com/
Software Category: AI-Medical Imaging/ Healthcare AI
Source: https://evidentvascular.com/evident-vascular-raises-series-b-financing-to-advance-ai-powered-intravascular-ultrasound-platform-technology/